156 related articles for article (PubMed ID: 38424308)
1. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract][Full Text] [Related]
2. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Li R; Barton HA
Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Caro L; Prueksaritanont T; Fandozzi CM; Feng HP; Guo Z; Wolford D; Panebianco D; Fraser IP; Levine V; Swearingen D; Butterton JR; Iwamoto M; Yeh WW
Clin Drug Investig; 2021 Feb; 41(2):133-147. PubMed ID: 33527237
[TBL] [Abstract][Full Text] [Related]
6. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
7. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
8. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
10. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
[TBL] [Abstract][Full Text] [Related]
11. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
[TBL] [Abstract][Full Text] [Related]
14. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
[TBL] [Abstract][Full Text] [Related]
15. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
[TBL] [Abstract][Full Text] [Related]
16. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
18. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
19. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Shoaf SE; Bricmont P; Repella Gordon J
Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]